A short while back I had said algorithms were one of the two hottest terms today in healthcare and this product is no exception as algorithms using thousands of patient data records are used to define brain dysfunction.
The software contains a database of brainwave recordings, which serves as the basis for developing profiles involving deviation from normal values against which a patient’s electrical brain activity can be compared. The zoon product is still awaiting approval from the FDA, but in short it will be a portable device to help medical professionals determine if and where brain damage has occurred. The device could have use with sports as far as being able to determine brain damage immediately from the playing field up on injury.
The technology used is somewhat old and controversial, qEEG (quantitative electroencephalogram). There are currently 4 university hospitals working with the device and the armed forces also have express an interest in the product as well, so now it’s up to the FDA. Michael Singer was recently hired from Revolution as the CEO. BD
The BrainScope Company, Inc. is developing a new generation of hand-held, simple-to-use, non-invasive instruments that, unlike existing technologies, can aid medical professionals and other trained users in quickly, accurately and objectively assessing brain function at the initial point of care, allowing patients suffering from brain dysfunctions to be promptly guided to appropriate treatment.
Everest Biomedical successfully developed two products with Bx elements that have already been proven on the market – the AUDIOscreener® infant brain monitor, which was sold to VIASYS Healthcare (now part of Cardinal Health), and SNAP II®, an intra-operative surgical monitor that was acquired by Stryker Corporation.
BrainScope’s first product ZOOM, now pending FDA clearance, is an advanced 8-channel brain electrical activity data collection system with post-hoc statistical analysis. The ZOOM system uses accepted methods of data selection, analysis, and feature extraction, including discriminant functions for probability of abnormality and other valuable information.
BrainScope’s first product ZOOM, now pending FDA clearance, is an advanced 8-channel brain electrical activity data collection system with post-hoc statistical analysis. The ZOOM system uses accepted methods of data selection, analysis, and feature extraction, including discriminant functions for probability of abnormality and other valuable information.
0 comments :
Post a Comment